Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ENTA vs CADL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CADL Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–3 Matrix Metrics)

CADL Overall Winner 6-Pillar Tally: ENTA 2 – 3 CADL (1 Tie) Matrix Metrics: ENTA 3 – 7 CADL

As of Nov 16, 2026, Candel Therapeutics, Inc. (CADL) is the stronger overall head-to-head candidate over Enanta Pharmaceuticals, Inc (ENTA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ENTA carries a Unified Composite Score of 46.2/100 (HOLD) at $10.79 (44.0x Forward P/E, -90.0% operating margin), whereas CADL carries 46.0/100 (HOLD) at $6.08 (43.5x Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: ENTA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0); meanwhile CADL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ENTA vs CADL
ENTA NASDAQ
Enanta Pharmaceuticals, Inc
Pharmaceutical Preparations
$10.79
-1.82% 1D
Market Cap $326.2M
TTM Revenue $65M
Forward P/E 44.0x
Beta / 30D Vol 0.89β · 58% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.6%), weak momentum, RSI 43
RSI-14: 43.0 · SMA20: $11.18 · SMA50: $11.88
CADL NASDAQ Head-to-Head Winner
Candel Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$6.08
-1.85% 1D
Market Cap $642.0M
TTM Revenue $31,000
Forward P/E 43.5x
Beta / 30D Vol 2.12β · 125% Vol
Unified Composite Score
46.0 / 100 HOLD
Tech 33.0 Fund 55.0 Flow 70.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.8%), weak momentum, RSI 31
RSI-14: 30.7 · SMA20: $8.33 · SMA50: $9.62

6-Pillar Scorecard Institutional Category Breakdown (ENTA 2 – 3 CADL)

Columns: Metric · ENTA · CADL
1. Valuation Multiples CADL
Forward P/E 44.0x 43.5x
Trailing P/E 44.0x 43.5x
PEG Ratio N/M N/M
EV / Revenue 5.3x N/M
2. Growth & Scale CADL
Revenue Growth (YoY) -21.6% +0.0%
Earnings Growth (YoY) -66.2% +0.0%
TTM Revenue (USD) $65M $31,000
Market Cap $326.2M $642.0M
3. Profitability & Quality CADL
Gross Margin 100.0% N/A
Operating Margin -90.0% 0.0%
Net Profit Margin -96.9% 0.0%
Return on Equity (ROE) -70.1% -93.7%
4. Balance Sheet & Cash Flow ENTA
Cash Generation (TTM) -$37M -$57M
Cash Flow Margin -56.6% N/A
Net Cash / Leverage $22M Net Debt (0.55x D/E) $152M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENTA
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 78.7% (11th %ile) 85.5% (18th %ile)
Put/Call OI Skew 0.31x (Call-Skewed) 0.50x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ENTA (3) vs CADL (7)
Institutional Metric ENTA CADL Criterion Row Edge
Market Capitalization
Scale
$326.2M $642.0M Larger Scale CADL
Trailing P/E Ratio
Valuation
44.0x 43.5x Lower Multiple CADL
Forward P/E Ratio
Valuation
44.0x 43.5x Lower Multiple CADL
Revenue Growth (YoY)
Growth
-21.6% +0.0% Higher Growth CADL
Operating Margin (TTM)
Profitability
-90.0% 0.0% Higher Margin CADL
Net Profit Margin
Profitability
-96.9% 0.0% Higher Margin CADL
Return on Equity (ROE)
Capital Efficiency
-70.1% -93.7% Higher ROE ENTA
52-Week Range Position
Momentum
10% ($10–$17) 18% ($4–$14) Stronger Trend CADL
Beta / 30D Volatility
Risk Regime
0.89β · 58% Vol 2.12β · 125% Vol Lower Realized Risk ENTA
Unified Institutional Score
Composite Signal
46.2 / 100 (HOLD) 46.0 / 100 (HOLD) Higher Composite ENTA
Trailing 12M Revenue (USD)
Operating Scale
$65M $31,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$37M ($22M Net Debt (0.55x D/E)) -$57M ($152M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ENTA +22.91 pp
ENTA: -2.79% · CADL: -25.7%
3M Horizon ENTA +30.63 pp
ENTA: -18.87% · CADL: -49.5%
6M Horizon ENTA +3.19 pp
ENTA: -19.78% · CADL: -22.97%
1Y Horizon CADL +39.94 pp
ENTA: -7.94% · CADL: +32.0%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ENTA Revenue CADL Revenue ENTA Op. Margin CADL Op. Margin Margin Leader
FY2018 $210M N/A 42.7% N/A ENTA
FY2019 $210M N/A 17.9% N/A ENTA
FY2020 $120M $0M -34.0% -11048.0% ENTA
FY2021 $100M $0M -112.9% -20580.8% ENTA
FY2022 $90M $0M -143.7% -27777.6% ENTA
FY2023 $80M N/A -173.2% N/A ENTA
FY2024 $70M N/A -179.9% N/A ENTA
FY2025 $70M N/A -130.7% N/A ENTA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ENTA BREAKDOWN
95d in phase · OBV NEUTRAL
Current IV 78.7%
IV Percentile 11th %ile
Put/Call OI Skew 0.31x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ENTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CADL BREAKDOWN
98d in phase · OBV DISTRIBUTION
Current IV 85.5%
IV Percentile 18th %ile
Put/Call OI Skew 0.50x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CADL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ENTA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $326.2M market capitalization and -90.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CADL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $642.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ENTA vs CADL Key Questions & Quantitative Answers

As of Nov 16, 2026, Candel Therapeutics, Inc. (CADL) is the stronger overall head-to-head candidate over Enanta Pharmaceuticals, Inc (ENTA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ENTA carries a Unified Composite Score of 46.2/100 (HOLD) at $10.79 (44.0x Forward P/E, -90.0% operating margin), whereas CADL carries 46.0/100 (HOLD) at $6.08 (43.5x Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: ENTA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0); meanwhile CADL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CADL leads the Growth & Scale pillar: ENTA posts -21.6% YoY revenue growth and -66.2% YoY earnings growth on $65M TTM revenue (100.0% gross margin, -90.0% operating margin), compared with CADL at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $31,000 TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ENTA cumulative revenue shifted -66.7% while CADL shifted N/A. In operating R&D and SG&A reinvestment, ENTA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CADL.

CADL screens cheaper on headline valuation multiples. ENTA trades at 44.0x Forward P/E, 44.0x Trailing P/E, N/M PEG, and 5.3x EV/Revenue (-56.6% FCF margin), whereas CADL trades at 43.5x Forward P/E, 43.5x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENTA (-70.1% ROE) versus CADL (-93.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ENTA carries 78.7% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 58% Vol realized risk). By comparison, CADL carries 85.5% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.50x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.12β · 125% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.